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Abstract 
Oral squamous cell carcinoma (OSCC) is genetically highly heterogeneous, which contributes to 
the challenges of treatment. To create an in vitro model that accurately reflects this 
heterogeneity, we generated a panel of HPV-negative OSCC cell lines. By whole exome 
sequencing of the lines and matched patient blood samples, we demonstrate that the mutational 
spectrum of the lines is representative of primary OSCC in The Cancer Genome Atlas. We 
show that loss of function mutations in FAT1 (an atypical cadherin) and CASP8 (Caspase 8) 
frequently occur in the same tumour. OSCC cells with inactivating FAT1 mutations exhibited 
reduced intercellular adhesion. Knockdown of FAT1 and CASP8 individually or in combination in 
OSCC cells led to increased cell migration and clonal growth, resistance to Staurosporine-
induced apoptosis and, in some cases, increased terminal differentiation. The OSCC lines thus 
represent a valuable resource for elucidating the impact of different mutations on tumour 
behaviour. 
 
Keywords Oral squamous cell carcinoma, Caspase 8, FAT1, whole exome sequencing 
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1. Introduction 
The global annual incidence of head and neck squamous cell carcinoma (HNSCC) is 
approximately 600,000, with over 300,000 deaths attributable to the disease each year (1). 
HNSCC lesions frequently recur and metastasize to other locations, contributing to significant 
morbidity and mortality (2). Despite improvements in surgical care and adjuvant therapy, the 5-
year survival rate is only 60% in the United States (3).  
 
Previous studies have used next-generation whole exome sequencing of primary tumours to 
reveal the mutational landscapes of human HNSCCs and suggest novel oncogenic drivers to 
target for potential therapies (4, 5, 6). HNSCC is strikingly heterogeneous at both the genetic 
and the cellular level. No single genetic lesion predominates and patients often develop more 
than one primary tumour.  
 
Oral cancer is a subtype of HNSCC, comprising tumours of the lip and oral cavity. Worldwide, 
over 250,000 new cases and 125,000 deaths from oral cancer occurred in 2008 (1). 
Approximately 90% of oral cancers are squamous cell carcinomas (SCCs), arising in the 
multilayered epithelia that line the mouth and lips. Oral SCC (OSCC) frequently involves the 
tongue, and can also occur in the floor of the mouth, gingiva, cheek and palate. The two major 
risk factors for OSCC are smoking and alcohol consumption (7). In contrast to HNSCC of the 
tonsils and oropharynx, OSCC tends not to be associated with HPV infection (8, 9). Despite 
advances in treatment, the survival rate for OSCC remains stubbornly low (3). 
 
As in other solid tumours (10, 11), the properties of the malignant epithelial cells in HNSCC elicit 
an immune infiltrate and activation of fibroblasts in the surrounding connective tissue stroma (1, 
3, 12). Integrative analysis of the genetic and cellular heterogeneity of HNSCC is beginning to 
reveal new biologically distinct subtypes of the disease (13) and greater understanding of their 
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significance could inform future therapies. One way to achieve this is by studying the properties 
of cells isolated from HNSCC.  
 
Cells can readily be cultured from human oral tumours and normal oral mucosa, and several 
well-annotated collections of HNSCC cells are available (14, 15, 16). However, genetic changes 
in individual cell lines have not been compared with control DNA from the original donors. Thus 
it has been difficult to discover whether the lines truly reflect the genetic heterogeneity of OSCC 
or are dominated by mutations acquired during long-term culture. The value of such lines lies in 
characterising the biology of genes that are frequently mutated in OSCC, including NOTCH1, 
CASP8 (Caspase 8) and FAT1 (an atypical cadherin) (6), that are not conventional 
oncogenes/tumor suppressor genes and can potentially have pleiotropic effects on tumour 
properties. For example, the association between FAT1 mutation and overall survival in HNSCC 
differs according to the HPV status of the tumour (17) and loss of Caspase 8 not only has cell 
intrinsic effects (18) but can also trigger inflammation (19). Furthermore, there is evidence for 
biological interactions between FAT1 and Caspase 8, with FAT1 acting as an antagonist of 
Caspase 8 in a synthetic lethal screen in cancer cell lines (20). 
 
In this study, we set out to develop new OSCC lines, discover which mutations are tumour-
acquired and determine whether they are indeed representative of mutational burden in primary 
tumours. We then used the lines to explore the impact of mutations in CASP8 and FAT1 on cell 
behaviour.  
 
 
2. Materials and Methods 
2.1. Derivation of OSCC Lines Anonymized biopsies of OSCC or normal oral mucosa were 
collected with appropriate ethical approval (UK National Research Ethics Service (08/H0306/30). 
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Cells were isolated and cultured on a feeder layer of J2 3T3 cells in complete FAD medium as 
described previously (16). 
 
2.2. Whole Exome Sequencing Genomic DNA was extracted from OSCC lines (passage 2-4) 
and patient-matched blood. Whole exome sequencing was performed by Beijing Genomics 
Institute (Hong Kong). Raw image files were processed by Illumina base calling Software 1.7 or 
base calling with default parameters, and the sequences of each individual were generated as 
90 bp paired-end reads. High-quality reads were aligned against the NCBI human reference 
genome (hg19) using Burrows-Wheeler Aligner (v0.5.9) with default parameters. Picard (v1.54) 
was employed to mark duplicates and was followed by Genome Analysis Toolkit (v1.0.6076, 
GATK IndelRealigner) to improve alignment accuracy. Putative somatic SNV were predicted by 
VarScan2.25 with the parameters as “-- min-coverage 5 --min-coverage-normal 5 --min-
coverage-tumour 5 --min-var-freq 0.1 --min-freq-for-hom 0.75 --min-avg-qual 0 —somatic-p-
value 0.15”. In order to obtain high confidence somatic SNVs, an in-house pipeline was applied. 
Somatic InDels were predicted by GATK SomaticInDelDetector with default parameters. A 
pipeline was developed to obtain high confidence somatic InDels; normal and tumour bam were 
reused to perform local realignment and germline indels were filtered for high confidence indels, 
with normal coverage and tumour coverage no less than 5. High confidence somatic single 
nucleotide variants and InDels were annotated using ANNOVAR. Functional impacts of 
missense mutations were predicted using SIFT, PolyPhen2, PhyloP, MutationTaster and LRT 
annotations.   
 
2.3. Prediction of driver genes and pathways The Oncodrive-fm method was applied, as 
previously published, to identify significantly mutant genes and KEGG pathways (21). Pathway 
enrichment analysis was also performed to identify additional significantly mutated KEGG 
pathways. 
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2.4. KEGG Pathway Analysis and Clustering Whole exome sequencing data from The 
Cancer Gene Atlas (TCGA) HNSCC collection (6) were accessed from cBioPortal.org. KEGG 
pathway analysis was performed, –log2(P) value were calculated and presented in heat maps 
created using GENE-E software (Broad Institute). OncoPrint, mutation diagrams and tests for 
mutual exclusivity of genomic alterations were downloaded from cBioPortal. 
 
2.5. Quantitative real-time RT-PCR RNA was harvested using the RNeasy Mini Kit and 
QIAshredder columns according to manufacturer’s instructions (Qiagen). cDNA was 
synthesized using SuperScriptTM III First-Strand Synthesis SuperMix (Invitrogen). qPCR was 
performed using TaqMan Fast Universal PCR Master Mix without AmpErase UNG (Life 
Technologies) on the CFX96 Touch Real-Time PCR Detection System (Bio-Rad) with the 
following primers: CASP8 (Hs01018151_m1), FAT1 (Hs00170627_m1) and GAPDH 
(Hs02758991_g1) as internal control (Life Technologies). Relative quantification was performed 
using the 1/∆Ct or ∆∆Ct methods.  
 
2.6. Transient transfection SMARTpool ON-TARGETplus CASP8 and FAT1 (GE Healthcare) 
and Silencer® Negative Control No.1 (Thermo Fisher) siRNAs were used. Prior to transfection, 
wells were coated with 20 µg/mL Rat Tail Collagen I (Corning) and incubated for 1 hour at 37°C. 
Cells were transfected using either Lipofectamine RNAiMax or Lipofectamine 2000 with Opti-
MEM medium (Thermo Fisher). The viability of transfected cells was confirmed by Trypan Blue 
exclusion prior to performing cell behaviour assays. 
 
2.7. Colony formation 48 hours after transfection, cells were seeded at clonal density in 6-well 
plates on a layer of feeders. 10-14 days after seeding, feeders were detached and keratinocytes 
were fixed in 10% formalin and stained with a solution of 1% Rhodamine B and 1% Nile blue. 
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Well images were acquired on the Gel Doc™ XR+ (Bio-Rad).  Percent well area covered by 
cells was determined using the ColonyArea plugin (22) for ImageJ. 
 
2.8. Cell Migration Assay 24 hours after transfection, cells were seeded on collagen-coated 
well plates in the Oris™ Cell Migration Assay (Platypus Technologies) and cultured in complete 
FAD medium. 24 hours after plating, cell seeding stoppers were removed. Phase-contrast 
images were acquired for 16-24 hours using an IncuCyte® ZOOM (Essen BioScience). Area 
closure was quantified in ImageJ, following the manufacturer’s instructions.  
 
2.9. Induction of apoptosis 24 hours after transfection, cells were seeded on collagen-coated 
96-well plates in complete FAD medium. 24 hours later cells were incubated with varying 
concentrations of Staurosporine (1285; Tocris) in complete FAD medium for 4 hours at 37°C.  
 
2.10. Immunofluorescence staining Cells were fixed in 4% paraformaldehyde, permeabilized 
using 0.5% Triton X-100 (Sigma-Aldrich) in PBS and blocked in a solution of 10% fetal bovine 
serum (Thermo Fisher), 0.25% gelatin from cold water fish skin (Sigma-Aldrich) and 0.5% Triton 
X-100 in PBS. Cells were incubated overnight at 4°C  with the following primary antibodies in 
blocking buffer: rabbit anti-Ki67 (1:50; ab16667; Abcam), Alexa Fluor® 488 conjugated anti-
cleaved Caspase-3 (Asp175) antibody (1:50 in blocking buffer; 9669; Cell Signaling) or mouse 
anti-transglutaminase 1 (TG1; clone BC1; 1:500). Cells were incubated for 1 hour at room 
temperature in blocking buffer with the following secondary antibodies, as appropriate: Alexa 
Fluor® 488 goat anti-rabbit IgG H+L (1:1000; ab150077; Abcam) or Alexa Fluor® 555 goat anti-
mouse IgG H+L (1:1000; ab150114; Abcam). Plasma membranes and nuclei were 
counterstained with CellMask™ Deep Red (1:1000 in PBS; C10046; Thermo Fisher) and DAPI 
(1 µg/mL in PBS), respectively, for 1 hour at room temperature. Following Caspase-3 labelling 
cell nuclei were counterstained with DRAQ5™ (5 µM in PBS; 108410; Abcam). Images were 
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acquired using the Operetta® High-Content Imaging System (PerkinElmer). Positive nuclear 
Ki67 and cytoplasmic TG1 immunostaining were quantified using an in-house pipeline on 
Harmony® software (PerkinElmer), while Caspase-3 positive cells were quantified using the 
“Apoptosis-1” module (PerkinElmer). 
 
2.11. Statistical Analyses Data were analyzed using an unpaired Student’s t test or one-way 
ANOVA with Tukey’s Multiple Comparison Post Test on GraphPad Prism 5.0b, and a P value of 
< 0.05 was considered significant, unless otherwise noted. 
 
3. Results  
3.1. Whole exome sequencing of OSCC lines We derived multiple low passage polyclonal 
cell lines from primary oral squamous cell carcinoma biopsies by culture on a 3T3 J2 feeder 
layer in order to minimise selection for rapidly dividing cells (16). Whole exome sequencing was 
performed on 16 lines, together with patient-matched blood. We achieved 37- and 43-fold mean 
sequence coverage of targeted exonic regions, with 73 and 77% of loci covered at ≥ 20-fold 
from tumour and matched blood samples, respectively (Supplementary Figure S1). Mutation 
rates varied from 2.50 – 44.7 mutations/megabase (mean 16.9 ± 13.5), with 80 – 1431 somatic 
mutations per sample (mean 539 ± 432) (Figure 1A; Supplementary Table S1). A total of 8629 
single nucleotide variations across 2611 genes were found, of which 5839 (68%) were 
synonymous, 2621 (30%) nonsynonymous, 125 (1.4%) stop-gains and 42 (0.49%) were splice-
site mutations (Supplementary Table S2). Ninety-five insertions/deletions (indels) were found 
across 83 genes, of which 36 (43%) and 27 (32.5%) were non-frameshift and frameshift 
deletions, respectively. Thirteen (16%) and 19 (23%) were non-frameshift and frameshift 
insertions, respectively. The ratio of nucleotide transitions to transversions ranged from 1.17 – 
3.00 (mean 2.24 ± 0.436) (Figure 1B). The frequency of C:G to A:T transversions and C:G to 
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T:A transitions varied inversely with mutation rate, while the frequency of T:A to C:G transitions 
increased with mutation rate. 
 
Ten of the 16 cell lines were derived from cancers of the tongue, four from the alveolus, one 
from the buccal mucosa and one from the hard palate (Figure 1C; Supplementary Table S1). No 
associations were detected between self-described alcohol consumption, tobacco history or 
age, nor between mutation rate or differentiation status of the primary tumour. However, well-
differentiated tumours tended to have a higher mutation rate than moderately differentiated 
tumours. All tumours were negative for common genotypes of human papilloma virus (HPV), 
determined by the absence of viral DNA integration in the sequenced exons.  
 
To identify putative driver genes and pathways that, when mutated, contribute to OSCC 
tumourigenesis, the Oncogene-fm method was applied (21). We considered significant only 
those mutated genes or Kyoto Encylclopedia of Genes and Genomes (KEGG) pathways with Q 
values < 0.10. Only two genes were found to be significantly mutated – the canonical tumour 
suppressor TP53 (p-value 1.49 x 10-9; q-value 3.72 x 10-7) and CSMD2 (CUB and sushi domain-
containing protein 2; p-value 0.00024; q-value 0.03013). While CSMD2 has a tumour 
suppressive role in several cancers (23, 24), CSMD2 mutations in HNSCC have not been 
described previously. 
 
Twenty KEGG pathways were significantly mutated across the 16 OSCC lines (Supplementary 
Table S3). Unsurprisingly, ten were pathways for specific cancers and three for other human 
diseases profiled in KEGG. Three cellular community pathways (Adherens Junction, Focal 
Adhesion and Tight Junction) and two signaling pathways (Wnt and B Cell Receptor Signaling 
Pathways) were also significantly mutated. Pathway enrichment analysis was performed in 
parallel, and seven KEGG pathways were significantly mutated with a corrected P value < 0.10 
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(Supplementary Table S4). Common pathways identified by both methods were Focal Adhesion 
and Wnt Signaling. The contribution of upregulated Wnt/β-catenin signaling to cell survival and 
invasion in HNSCC has been previously discussed (15, 25, 26). Recent work suggests that 
transcriptional regulation of focal adhesion genes plays a crucial role in OSCC pathogenesis 
and that focal adhesion kinase (FAK) is a key mediator of extra-cellular matrix interactions and 
cellular signaling contributing to HNSCC onset and progression (27, 28). 
 
In 2015, The Cancer Gene Atlas (TCGA) Network published genomic profiles for 279 HNSCCs 
(6). Of the 11 genes identified in that study as significantly mutated and eight trending towards 
significance, nine and five, respectively, were identified as harboring somatic mutations across 
13 of our 16 cell lines (Figure 1D). These include inactivating NOTCH1 mutations (found in 10-
15% of HNSCC) (4, 5, 6), which cluster to the EGF-like binding domain and domains necessary 
for transactivation of target genes. Tumour-associated NOTCH1 mutations were identified in 
three of our OSCC lines via whole exome sequencing (Figure 1D). In addition, Sanger 
sequencing of the entire genomic region of NOTCH1-3 was performed on all OSCC lines, 
including lines for which matched blood was not available. This identified several additional 
novel bona fide somatic (nonsynonymous, nonsense and indel) mutations (Supplementary 
Figure 2). 44% of the cell lines contained mutations in NOTCH1, many of the mutations 
clustering in the EGF-like domain. Mutations in NOTCH2 and 3 were less common. The 
presence of mutations in the PEST domain of NOTCH3 could potentially result in increased 
receptor activity due to decreased ubiquitin-mediated degradation.  
 
3.2. OSCC lines are representative of primary tumour heterogeneity To discover whether 
the mutational spectrum of OSCC is distinct from that of other HNSCCs, we determined the site 
of origin of each of 267 tumours in TCGA and then performed unsupervised clustering of the 
samples according to the significance of mutated KEGG pathways (Figure 1E). This indicated 
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that the spectrum of KEGG pathways mutated in OSCC were similar to those of HNSCC arising 
in other sites.  
 
To determine whether the KEGG pathways that were mutated in the OSCC lines were similar to 
those in primary tumours, we performed unsupervised clustering of TCGA OSCC samples 
ranked according to the frequency of mutated KEGG pathways in the cell lines. As shown in 
Figure 1F, the pathways that were mutated in the lines were indeed representative of those in 
primary tumours.   
 
3.3. Mutations in CASP8 and FAT1 To evaluate the impact of mutations and expression of 
putative driver genes established by genomic studies on OSCC cell behaviour, we conducted a 
systematic literature review of genes implicated in homeostasis or disease in stratified 
squamous epithelia through regulation of adhesion, invasion or motility. We focused on genes 
that were members of multiple mutated non-tissue specific KEGG pathways and/or were most 
significantly mutated in our study and TCGA. We prioritized those genes harbouring mutations 
in more than 8% of HNSCCs and at least two of our cell lines. Seven genes were identified – 
PLEC, CASP8, SYNE2, FAT1, LRP1B, COL11A1 and HUWE1 (Figure 2A). We also queried 
TCGA for pair associations of mutations across these genes in HNSCC (Figure 2B). CASP8 
and FAT1 (P value = 0.0003), and SYNE2 and LRP1B (P value = 0.015) were identified as 
frequently co-mutated in HNSCC.  
 
Of the 279 patients with HNSCC reported by TCGA in 2015 (6), 172 patients had tumors of the 
oral cavity and the other 107 had tumors of the oropharynx (n = 33), hypopharynx (n =2) and 
larynx (n = 72). Considering copy number alterations and truncating, missense and in-frame 
mutations, 23% of tumors of the oral cavity harbored mutations in FAT1 alone, 5.8% in CASP8 
alone and 9.3% in both FAT1 and CASP8, compared with 22%, 2.8% and 1.9%, respectively, in 
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tumors of other areas of the head and neck. The increased frequency of CASP8 and FAT1 co-
mutations in OSCC relative to other HNSCC,  recent evidence suggesting functions of CASP8 
that extend beyond programmed cell death (29), and uncertainty surrounding the role of FAT1 in 
oncogenesis (30) led us to focus on these two genes.  
 
Whole exome sequencing revealed eight putative inactivating somatic mutations in FAT1 across 
four of the 16 OSCC lines, and three in CASP8 across three lines (Figure 2C). Inactivating 
mutations were defined as frameshift indels, and splice-site, nonsense and missense mutations 
predicted to be deleterious to protein function by ANNOVAR. Two lines simultaneously harbored 
mutations in both FAT1 and CASP8. Similar to the gene span of inactivating mutations in TCGA, 
mutations in FAT1 and CASP8 did not localize to any particular protein domain.  
 
We next determined mRNA levels of CASP8 and FAT1 in OSCC cell lines by Q-PCR (Figure 
2D). There was no significant difference between CASP8 levels in wild type and mutant lines, 
nor between OSCC cells and normal oral keratinocytes. However, there was a trend for lower 
FAT1 mRNA levels in FAT1 mutant lines compared to wild type (P value < 0.05). In addition, 
FAT1 mRNA levels were higher in normal oral keratinocytes than OSCC lines (Figure 2D). 
These observations were consistent with primary tumour data from TCGA, since CASP8 mRNA 
levels in tumours with mutant CASP8 did not differ from those with wild type CASP8 at a given 
copy number, whereas there was a trend to lower FAT1 mRNA levels in tumours bearing FAT1 
mutations (Figure 2E). 
 
3.4. Phenotypic effects of loss or inactivation of CASP8 and FAT1 To characterise the 
effect of FAT1 mutations on OSCC lines we first observed the morphology of cells grown on 
feeders. As shown in Figure 3A, cells with FAT1 mutations tended to form less cohesive 
colonies than cells that were wild type for FAT1. However, FAT1 knockdown in SJG-33 cells, 
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which are wild type for FAT1, was not sufficient to reduce cell-cell adhesion (Figure 3A, B). We 
also observed that the level of FAT1 mRNA increased with increased cell density in cells with 
wild type but not mutant FAT1 (Figure 3B). This did not correlate with the level of FAT1 mRNA 
in cells at low density and was more marked in OSCC lines than in control oral keratinocytes. 
 
To determine the impact of FAT1 expression on the growth of OSCC cells in culture, we 
performed siRNA-mediated knockdown in cells with wild type FAT1 (Supplementary Figure 3A) 
and then compared clonal growth with cells expressing scrambled control siRNA (Figure 3C, D; 
Supplementary Figure 3B). We also examined cells in which we knocked down CASP8, alone 
or in combination with FAT1 knockdown. We observed that knockdown of each gene, alone or 
in combination, stimulated clonal growth of OSCC in culture but had no effect on the growth of 
primary oral keratinocytes. 
 
Given the association between FAT1 mutation and cell-cell adhesion (Figure 3A) and between 
CASP8 and integrin-mediated cell migration (29), we next examined the effect of knockdown on 
cell migration. We monitored the ability of cells to migrate into a circular area exposed in the 
centre of the culture dish during a 24h period. In the case of mutant cells, there were frequent 
individual cells that had migrated into the area independently of the migrating epithelial front 
(Figure 3E). Quantitation of the assays showed that knockdown of FAT1 or CASP8 alone and in 
combination increased cell migration in OSCC but not in primary keratinocytes (Figure 3F). In 
some cases the effect of CASP8 knockdown was greater than that of FAT1 (e.g. SJG-8, SJG-32, 
which harbor FAT1 mutations), whereas in others knockdown of CASP8 and FAT1 individually 
or in combination were equally effective (SJG-6, SJG-17).  
 
The impact of CASP8 and FAT1 knockdown on clonal growth could not be accounted for by an 
increase in proliferation, and in several cases Ki67 labelling was, rather, reduced (Figure 4A). 
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Knockdown of CASP8 and FAT1 did not have a consistent effect on the proportion of cells that 
underwent terminal differentiation, as judged by the percentage of cells expressing 
Transglutaminase 1: there was no effect of double knockdown on SJG-17 cells; differentiation 
was stimulated in SJG-33 cells; and decreased in SJG-41 cells (Figure 4B). Knockdown of 
CASP8 and FAT1 did, however, increase resistance to Staurosporine-induced apoptosis 
(Supplementary Figure 4), as judged by Caspase-3 immunostaining (Figure 4C).  
 
We conclude that loss of function mutations in CASP8 and FAT1 are likely to confer a growth 
advantage on OSCC by reducing cell-cell adhesion, promoting cell migration and conferring 
resistance to apoptosis. Furthermore, as expected, knockdown tended to have more 
pronounced effects in cells with wild type CASP8 and FAT1. 
 
4. Discussion  
While many investigators have generated cell lines from human HNSCC and used them to 
study the biology of this tumour type (14, 15, 16), our study is the first to derive cell lines for 
which matching normal patient DNA is available. Furthermore, we demonstrate that the 
spectrum of tumour-acquired mutations is representative of that found in tumour biopsies, for 
example in the case of NOTCH1-3 (6, 15). These lines will be of considerable value for studying 
tumour cell behaviour in vitro and in xenograft assays. 
 
As proof of the utility of the lines, we studied the impact of loss of functional CASP8 and FAT1, 
two genetic changes that, we found, frequently occur together in individual OSCC. We found 
that in the lines, as in primary tumours, inactivating mutations in CASP8 did not result in a 
reduction in CASP8 expression, whereas FAT1 mutation did correlate with reduced mRNA 
levels. While FAT1 mutant lines showed reduced intercellular adhesion, FAT1 knockdown in a 
wild type line was not sufficient to cause a significant change in morphology. It will therefore be 
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of interest to discover whether the effect of FAT1 loss is dependent on other OSCC mutations 
(Figure 1D). For example, mutations in PTEN will affect the actin cytoskeleton (31) and AJUBA 
mutations are likely to impact E-cadherin mediated cell adhesion (32). Furthermore, although 
we have not explored the underlying mechanism by which FAT1 mRNA levels increase in some 
cell lines with increasing cell density but not in others (Figure 3B), this has the potential to affect 
cell behaviour via an impact on HIPPO signalling (30). 
 
Knockdown of each gene in cells that were wild type for CASP8 and FAT1 confirmed a clonal 
growth advantage, consistent with the observation that CASP8 mutant cells are more 
aggressive in tongue xenografts (15). This could be attributed, at least in part, to increased cell 
migration and reduced apoptosis, rather than to an increase in the proportion of actively cycling 
cells. The consequences of stimulation of terminal differentiation, observed in some cells, 
remain to be explored but could potentially lead to increased release of cytokines such as IL-6 
that render the microenvironment permissive for tumour growth (31) and altered inflammatory 
signalling in CASP8 mutant cells (19). Cells that show a more pronounced phenotype on 
combined knockdown of CAS8 and FAT1 will be useful for exploring the cancer relevance of the 
observed antagonistic interactions between FAT1 and Caspase 8 (20). 
 
In conclusion, OSCC is highly heterogeneous at both the cellular and genetic levels. The panel 
of cell lines that we have characterised will be useful for identifying the signalling pathways that 
are affected by particular combinations of mutations and for discovering how they act both at the 
level of the cells that bear the mutations and at the level of the surrounding stroma and immune 
infiltrate. In the long term, this type of approach has the potential to suggest new combination 
therapies to improve the outcome for patients with OSCC. 
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Figure Legends 
Fig. 1. Genomic analysis of OSCC lines and TCGA HNSCC tumours. A-C) Somatic mutation 
rates (A), nucleotides transition and transversion frequencies (B), clinical characteristics and 
social histories (C) of cell lines and patients from which they were derived. D) Somatic single 
nucleotide variants (SNVs) and insertion/deletions (indels) in significantly mutated genes. 
Genes are ranked in order of significance from TCGA (6). E) Unsupervised clustering of TCGA 
HNSCC samples according to significance of mutated KEGG pathways. Rows are individual 
tumours; columns are KEGG pathways. OSCC are shown separately from other HNSCC. F) 
Unsupervised clustering of TCGA OSCC samples ranked according to frequency of mutated 
KEGG pathways (descending rank order) in OSCC cell lines. Rows are pathways and columns 
are individual tumours. (E, F) Color scale is based on –log2(P) values.  
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Fig 2. Identification of CASP8 and FAT1 as putative HNSCC/OSCC drivers. A) Genetic 
alterations in putative driver genes identified by exomic sequencing and literature review. 
Samples are arranged to emphasize mutual exclusivity among mutations. Samples without 
genetic alterations in these genes are not shown. B) Pair associations of genetic alterations 
among putative driver genes in TCGA HNSCC project. P value was determined by Fisher’s 
Exact test. C.O. = co-occurrence, M.E. = mutually exclusive. C) Genetic alterations in CASP8 
and FAT1 in TCGA HNSCC and OSCC cell line datasets. LAGD = laminin a-g domain; EGFLR 
= EGF-like repeat; asterisk indicates mutation present in both TCGA and cell line datasets.  D) 
mRNA expression of CASP8 and FAT1 in OSCC cell lines. P value was determined by unpaired 
Student’s t-test. *P < 0.01 – 0.05.  No significant difference was detected between presence of 
CASP8 mutations and CASP8 mRNA expression. OK and CRI-005 are two strains of primary 
oral keratinocytes. mut = mutant, wt = wild type. E) CASP8 mRNA levels in tumours with mutant 
and wild type CASP8 (right hand panel) and FAT1 mRNA levels in tumours with mutant and wild 
type FAT1 (left hand panel) stratified by putative copy-number alterations. Data from TCGA (6). 
 
Fig. 3. Phenotypic impact of CASP8 and FAT1 mutations and siRNA knockdown in OSCC 
lines. A) Phase-contrast microscopy of OSCC lines with (mt) and without (wt) predicted 
inactivating mutations in FAT1, and effects of FAT1 siRNA on SJG-33 (wt for FAT1). B) FAT1 
mRNA expression in OSCC lines plated at low and high density for 48-72 hours. OK = primary 
oral keratinocytes. C, D) Impact of CASP8 and FAT1 knockdown on clonal growth. (C) Triplicate 
dishes of SJG-17 cells. (D) Percent well area covered by cell clones. Significant differences 
from non-targeting control siRNA (siSCR) are shown. A-D) Cells were cultured on feeders. E, F) 
Impact of CASP8 and FAT1 knockdown on cell migration. (E) Representative images of cells at 
start (0h) or 24h later. In high magnification view, arrow indicates migratory cell front; asterisks 
indicate individual migrating cells. (F) Migration rate, defined as fold change in area of central 
detection zone at 16 – 24 hours. Data are presented as mean ± SEM. (E, F) Cells were plated 
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in the absence of feeders. (D, F) P values were determined by ANOVA and Tukey’s test. *P < 
0.01 – 0.05, **P < 0.001 – 0.01, ***P < 0.0001 – 0.001.  
 
Fig. 4. Impact of CASP8 and FAT1 siRNA knockdown on proliferation, differentiation and 
apoptosis. A) Proliferation was assessed by Ki67 immunostaining. Significant differences from 
non-targeting control siRNA (siSCR) are shown. wt = wild type, mut = mutant, OK = primary oral 
keratinocytes. B) Terminal differentiation was assessed by transglutaminase 1 (TGM1) 
immunostaining. A, B) Plasma membranes and nuclei were counterstained with CellMask™ 
Deep Red and DAPI. C) Cells were incubated with Staurosporine, and apoptosis was measured 
by Caspase-3 (CASP3) immunostaining. (A-C) Representative images are shown for SJG-33 
(A), control O.K. and SJG-6 (B), siCASP8 and siCASP8/FAT1 SJG-41 (B) and SJG-17 (C). 
Data are presented as mean ± SEM. P value was determined by ANOVA and Tukey’s test. *P < 
0.01 – 0.05, **P < 0.001 – 0.01, ***P < 0.0001 – 0.001. Scale bars 100 µm. 
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Supplementary Table S1: Clinical and genomic information for OSCC patient-
derived cell lines. Alcohol and smoking histories were self-reported. All other 
information was reported by the patient’s providers. Statistics listed are for somatic 
mutations. Alcohol: No = does not drink, Minimal ≤ 1 drink per day for women or 2 
drinks for men, Moderate = 5-7 drinks per week for women or 10-14 drinks for men, 
Heavy ≥ 8 drinks per week for women or 15 for men. Anatomical site: RMT = 
retromolar trigone. Differentiation: describes tumor biopsy from which lines were 
derived. Mb = megabase. 
 
Supplementary Table S2: Somatic mutations in OSCC lines. Mutations presented 
were detected by whole exome sequencing and annotated using ANNOVAR.  
 
Supplementary Tables S3-4: Significantly mutated pathways in OSCC lines. 
Mutated KEGG pathways were identified using (S3) the Oncodrive-fm method 
(Gonzalez-Perez & Lopez-Bigas, 2012) or (S4) via pathway enrichment analysis. 
 
Supplementary Figure S1: Whole exome sequencing coverage and depth. A) 
Distribution of coverage. Box-and-whisker plots display the average percentage of 
targeted bases at various fold-coverages across 16 tumor-derived cell lines (T) and 
normal patient-matched blood (N). B) Distribution of depth. Box-and-whisker plots 
display the average sequencing depth across all targeted regions.  
 
Supplementary Figure S2: Sanger sequencing of OSCC lines identifies novel 
mutations in NOTCH1-3. Numbers represent tissue ID of cell lines, including those 
for which patient-matched blood was not available. Triangles represent localization of 
mutation in protein. NECD = Notch extracellular domain, NTMIC = Notch transmembrane 
and intracellular domain, EGF = epidermal growth factor-like repeats, NRR = 
negative regulatory region, LNR = Lin-12/Notch repeats, HD = heterodimerization 
domain, TMD = transmembrane domain, RAM = Rbp-associated molecule domain, 
ANK = ankyrin repeat domain, PEST = proline, glutamic acid, serine and threonine 
sequence. 
 
Supplementary Figure S3: A, B) siRNA knockdown efficiency. Quantitative real-
time RT-PCR was performed on transcripts harvested 48 hours after transfection. LF 
= Lipofectamine. (B) SJG-33 cells. C) Representative colony formation assays. 
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Supplementary Figure S4: Staurosporine-induced apoptosis assay. A) 
Representative images of SJG-6 cells treated with varying concentrations of 
Staurosporine for 4 hours in complete FAD medium and stained for active Caspase-3. 
B-C) Dose response curves for Staurosporine treatment (B) using positive Caspase-
3 as a readout for apoptotic cells and (C) measuring nuclear fragmentation index and 
mean nucleus area with the “Apoptosis-1” module on Harmony software. Scale bars 
100 µm. 
 
Reference 
Gonzalez-Perez A, Lopez-Bigas, N. Functional impact bias reveals cancer drivers. 
Nucleic Acids Res 2012;40:e169. 
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Highlights 
• Generation of human oral squamous cell carcinoma lines with whole 
exome sequence data 
• Mutational spectrum of the lines is representative of primary tumours 
• Loss of function mutations in FAT1 and CASP8 frequently co-occur 
• Inactivating FAT1 mutations correlate with reduced intercellular 
adhesion 
• Inactivation of FAT1 and CASP8 results in increased clonal growth, 
migration and apoptosis resistance 
